{
    "nctId": "NCT00100893",
    "briefTitle": "IH636 Grape Seed Extract in Preventing Breast Cancer in Postmenopausal Women at Risk of Developing Breast Cancer",
    "officialTitle": "A Phase I Prevention Trial of ACTIVIN Grape Seed Extract as an Aromatase Inhibitor In Healthy Postmenopausal Women at Risk for Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 37,
    "primaryOutcomeMeasure": "Estrogen suppression as measured by serum estradiol, estrone, estrone sulfate, and sex hormone binding globulin",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* At risk of developing breast cancer\n* No history of breast cancer or ductal carcinoma in situ\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 40 to 75\n\nSex\n\n* Female\n\nMenopausal status\n\n* Postmenopausal, defined by 1 of the following criteria:\n\n  * No spontaneous menses for \u2265 12 months\n  * Prior bilateral oophorectomy\n  * Prior hysterectomy with follicle-stimulating hormone within menopausal range\n\nPerformance status\n\n* ECOG 0-1\n\nLife expectancy\n\n* Not specified\n\nHematopoietic\n\n* Hemoglobin \u2265 9.0 g/dL\n* Platelet count \u2265 100,000/mm\\^3\n* WBC \u2265 3,500/mm\\^3\n* Absolute granulocyte count \u2265 1,500/mm\\^3\n* No coagulation disorders\n\nHepatic\n\n* SGOT and SGPT \u2264 2 times upper limit of normal (ULN)\n* Bilirubin \u2264 1.5 times ULN\n\nRenal\n\n* Creatinine \u2264 1.5 times ULN\n\nCardiovascular\n\n* No major illness of the cardiovascular system\n\nPulmonary\n\n* No major illness of the respiratory system\n\nOther\n\n* No history of other invasive cancer within the past 5 years except squamous cell or basal cell skin cancer\n* No major systemic infection\n* No Cushing's syndrome or adrenal insufficiency\n* No osteoporosis, defined as a bone mineral density T-score \u2265 -2.5 on dual-energy x-ray absorptiometry scan (calcium and/or cholecalciferol \\[vitamin D\\] supplementation AND/OR bisphosphonate therapy allowed provided participant is on a stable dose during study participation)\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* Not specified\n\nChemotherapy\n\n* Not specified\n\nEndocrine therapy\n\n* More than 3 months since prior hormone-modifying medications, including any of the following:\n\n  * Oral contraceptives\n  * Hormone replacement therapy\n  * Selective estrogen receptor modifiers\n  * Aromatase inhibitors\n  * Gonadotropin-releasing hormone modifiers\n* Concurrent dehydroepiandrosterone (DHEA) allowed, provided dose remains constant during study participation\n\nRadiotherapy\n\n* Not specified\n\nSurgery\n\n* Not specified\n\nOther\n\n* No red wine, red grapes, or white button mushrooms directly before or during study treatment\n\n  * White and seedless grapes allowed\n* No other concurrent therapy",
    "sex": "FEMALE",
    "minimumAge": "40 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}